德孚在中国

9 5 9 0 3

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





已发表论文

用于口服递送的大黄酸加载聚纳米粒 (乳酸-共- 乙醇酸) 的制备、表征和体内研究 

 

Authors Yuan Z, Gu XH

Published Date April 2015 Volume 2015:9 Pages 2301—2309

DOI http://dx.doi.org/10.2147/DDDT.S81320

Received 21 January 2015, Accepted 6 March 2015, Published 21 April 2015

Abstract: A novel rhein formulation based on poly(lactic-co -glycolic acid) (PLGA) nanoparticles (NPs) suitable for oral administration was developed in this study. The designed nanosystems were obtained by a modified spontaneous emulsification solvent diffusion method. The morphology of rhein-loaded PLGA NPs showed a spherical shape with a smooth surface, without any particle aggregation. Mean size of the NPs was 140.5±4.3 nm, and the zeta potential was -16.9±3.1 mV. The average drug loading was 3.9%±0.7%, and encapsulation efficiency was 84.5%±6.2%. Meanwhile, NPs are characterized by the slower release (only about 70% of rhein is released within 5 hours), and the model that fitted best for rhein released from the NPs was Higuchi kinetic model with correlation coefficient r =0.9993, revealing that rhein could be controlled released from the NPs. In vivo, NPs altered the distribution of rhein, and the half-life after oral administration was prolonged remarkably more than those of suspensions (22.6 hours vs 4.3 hours). The pharmacokinetic results indicated that the NPs had sustained-release efficacy. The area under the curve0–∞ of the NPs formulation was 3.07-fold higher than that of suspensions, suggesting that the encapsulated rhein had almost been absorbed in rats over the period of 12 hours. Although rhein-loaded PLGA NP formulations are hopefully used as a chemotherapeutic or adjuvant agent for human gastric cancer (SGC-7901), their in vivo antitumor effect and mechanisms at the molecular level still need further study.
Keywords: rhein, PLGA, nanoparticles, release, pharmacokinetics, SGC-7901






Download Article[PDF]